Dr. Michael Hofman: PSMA Theranostics in Oncology | Ep. 14

In this episode of The Oncology Insights Podcast, I speak with Dr. Michael Hofman, a nuclear medicine physician and professor at Peter MacCallum Cancer Centre, about the evolution of theranostics and targeted radiopharmaceutical therapy. We examine radioactive iodine, PSMA PET imaging, lutetium 177 therapy, prostate cancer applications, and opportunities to expand these approaches across oncology. Listen now on all major platforms!

“Lutetium 177 delivers targeted radiation over a short distance after binding to tumor cells, helping limit radiation exposure across most normal tissues.”

Meet the guest: Dr. Michael Hofman is a nuclear medicine physician and professor at Peter MacCallum Cancer Centre whose research focuses on PSMA PET imaging, radioligand therapy, and prostate cancer. He has led multicenter clinical trials supporting advances in targeted cancer imaging and treatment, published more than 300 papers, and secured substantial research funding. Listen to Dr. Michael Hofman on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:34) Introduction
• (08:15) Theranostic imaging
• (17:49) Targeted radiation
• (23:46) PSMA development
• (26:46) PSMA imaging
• (28:15) Prostate therapy
• (31:15) Final Questions

The Oncology Insights Podcast is trusted and supported by innovative companies like:

- ZentrixOS

- Zentrix Insights

- Elevate

- WiseVAs

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast